Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the National Cancer Plan on support for people with brain tumours.

The Department recognises that there are currently limited treatment options available for people who have been diagnosed with brain tumours.

The National Cancer Plan, published on 4 February 2026, complements the 10-Year Health Plan and sets out how the National Health Service will improve outcomes for all cancer patients including those with rarer and less common cancers such as brain tumours.

Patients with rare cancers, including brain tumours, will benefit from a move to specialist multi-disciplinary teams which cover multiple providers. This will allow them to benefit from the input of specialist centres and so access to the best evidence-based care.

To meet its obligations for rare cancers, including brain tumours, the Government will appoint a new national clinical lead for rare cancers. This national clinical lead will have a clear mandate to speak up for rare cancers, and to provide clinical advice and support for the delivery of the actions in the plan.

In January 2026, the National Institute for Health and Care Research (NIHR) announced increased investment of over £25 million in the NIHR Brain Tumour Research Consortium. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours – ultimately reducing lives lost to cancer.

In addition to speeding up diagnosis and treatment, the work being undertaken by the consortium aims to ensure that patients have access to the latest treatments and technology and to clinical trials. This will make a significant contribution to bringing the United Kingdom’s cancer survival rates back up to the standards of the best in the world.